Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPEPPS | P55786 | 3/20 | 0.43 |
| ▸ | GFER | P55789 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | G6PD | P11413 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17577923 | 0.78 | GAA (0.42) | ALDH1A1GAAG6PDL3MBTL1ALOX5 | |
| SCHEMBL17577892 | 0.73 | MAOB (0.42) | ALDH1A1GAAG6PDL3MBTL1ALOX5 | |
| SCHEMBL16488067 | 0.65 | ALDH1A1 (0.44) | ALDH1A1MAPTRIPK1KDM4EKMT2A | |
| SCHEMBL20993167 | 0.65 | RIPK1 (0.48) | NPEPPSGFERALDH1A1MAPTRIPK1 | |
| SCHEMBL12002257 | 0.64 | MAPT (0.47) | NPEPPSGFERALDH1A1MAPTRIPK1 | |
| SCHEMBL3182932 | 0.64 | CHRNB2 (0.56) | ALDH1A1MAPT | |
| SCHEMBL14235834 | 0.64 | CHRNB2 (0.56) | ALDH1A1MAPT | |
| SCHEMBL29352077 | 0.64 | CHRNB2 (0.56) | ALDH1A1MAPT | |
| SCHEMBL6884740 | 0.64 | RIPK1 (0.57) | NPEPPSALDH1A1MAPTRIPK1KMT2A | |
| SCHEMBL19463939 | 0.64 | CHRNB2 (0.56) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991997-B1 | TRANSITION METAL COMPLEXES WITH CARBENE LIGANDS AND THE USE THEREOF IN OLEDS | UDC IRELAND LTD (IE) | 2018-02-21 | — | — | EP | disclosed |
| US-20160072081-A1 | Transition metal complexes with carbene ligands and the use thereof in OLEDs | BASF SE (DE) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160072081-A1 | Transition metal complexes with carbene ligands and the use thereof in OLEDs | OCIAD1, OCIAD2, TRPM6 | NPEPPS 4191/4885GFER 2837/4885ALDH1A1 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.